XERS insider buying and SEC filings, explained
Xeris Biopharma Holdings, Inc. · CIK 1867096
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$978K
Planned sales (10b5-1)
$4.4M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 1, 2026 | Planned (10b5-1) | Steven Pieper (CFO) sold 5,000 shares at about $9.41 ($47K), marked as a 10b5-1 plan trade. Holdings down <1% to 1,351,053 shares. | SEC filing Filed Oct 2, 2026, 4:54 PM ET |
| Oct 1, 2026 | Planned (10b5-1) | Kevin McCulloch (President / COO) sold 15,000 shares at about $9.41 ($141K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,599,208 shares. | SEC filing Filed Oct 2, 2026, 4:54 PM ET |
| Oct 1, 2026 | Planned (10b5-1) | Beth Hecht (Chief Legal Officer) sold 16,666 shares at about $9.41 ($157K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,111,130 shares. | SEC filing Filed Oct 2, 2026, 4:54 PM ET |
| Sep 28, 2026 | Planned (10b5-1) | Kevin McCulloch (President / COO) sold 25,000 shares at $10.00 ($250K), marked as a 10b5-1 plan trade. Holdings down 2% to 1,614,208 shares. | SEC filing Filed Sep 29, 2026 |
| Sep 1, 2026 | Planned (10b5-1) | Kevin McCulloch (President / COO) sold 15,000 shares at about $8.49 ($127K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,639,208 shares. | SEC filing Filed Sep 1, 2026 |
| Sep 1, 2026 | Planned (10b5-1) | Steven Pieper (CFO) sold 5,000 shares at $8.50 ($43K), marked as a 10b5-1 plan trade. Holdings down <1% to 1,356,053 shares. | SEC filing Filed Sep 1, 2026 |
| Sep 1, 2026 | Planned (10b5-1) | Beth Hecht (Chief Legal Officer) sold 16,666 shares at about $8.49 ($141K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,127,796 shares. | SEC filing Filed Sep 1, 2026 |
| Aug 12, 2026 | Planned (10b5-1) | Steven Pieper (CFO) sold 5,000 shares at $8.50 ($43K), marked as a 10b5-1 plan trade. Holdings down <1% to 1,361,053 shares. | SEC filing Filed Aug 12, 2026 |
| Aug 3, 2026 | Planned (10b5-1) | Kevin McCulloch (President / COO) sold 15,000 shares at about $8.02 ($120K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,676,126 shares. | SEC filing Filed Aug 4, 2026 |
| Aug 3, 2026 | Planned (10b5-1) | Beth Hecht (Chief Legal Officer) sold 16,666 shares at about $8.01 ($133K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,144,462 shares. | SEC filing Filed Aug 4, 2026 |
| Jul 6–7, 2026 | Planned (10b5-1) | Steven Pieper (CFO) sold 45,000 shares between Jul 6 and Jul 7 at about $8.51 ($383K), marked as a 10b5-1 plan trade. Holdings down 3% to 1,366,053 shares. | SEC filing Filed Jul 7, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Kevin McCulloch (President / COO) sold 90,000 shares at about $8.03 ($723K), marked as a 10b5-1 plan trade. Holdings down 5% to 1,691,126 shares. | SEC filing Filed Jul 2, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Beth Hecht (Chief Legal Officer) sold 16,666 shares at about $8.03 ($134K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,161,128 shares. | SEC filing Filed Jul 2, 2026 |
| Jun 4, 2026 | Planned (10b5-1) | Dawn Halkuff (Director) sold 20,000 shares at about $6.09 ($122K), marked as a 10b5-1 plan trade. Holdings down 17% to 95,000 shares. | SEC filing Filed Jun 5, 2026 |
| Jun 4, 2026 | Planned (10b5-1) | Barbara-Jean Anne Bormann-Kennedy (Director) sold 16,000 shares at about $6.09 ($97K), marked as a 10b5-1 plan trade. Holdings down 11% to 126,500 shares. | SEC filing Filed Jun 5, 2026 |
| Jun 4, 2026 | Planned (10b5-1) | John Johnson (Director) sold 15,000 shares at about $6.09 ($91K), marked as a 10b5-1 plan trade. Holdings down 2% to 683,083 shares. | SEC filing Filed Jun 5, 2026 |
| Jun 3, 2026 | Planned (10b5-1) | Marla Persky (Director) sold 15,500 shares at about $5.90 ($91K), marked as a 10b5-1 plan trade. Holdings down 11% to 126,500 shares. | SEC filing Filed Jun 5, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | Beth Hecht (Chief Legal Officer) sold 16,667 shares at about $6.06 ($101K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,176,506 shares. | SEC filing Filed Jun 2, 2026 |
| May 1, 2026 | Planned (10b5-1) | Beth Hecht (Chief Legal Officer) sold 16,667 shares at about $6.23 ($104K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,193,173 shares. | SEC filing Filed May 1, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Beth Hecht (Chief Legal Officer) sold 16,667 shares at about $5.99 ($100K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,209,840 shares. | SEC filing Filed Apr 3, 2026 |
| Mar 30, 2026 | Planned (10b5-1) | James Aloysius Brady (Director) sold 10,834 shares at about $5.54 ($60K), marked as a 10b5-1 plan trade. Holdings down 11% to 89,166 shares. | SEC filing Filed Apr 1, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Beth Hecht (Chief Legal Officer) sold 16,667 shares at about $6.24 ($104K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,226,507 shares. | SEC filing Filed Mar 4, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | Beth Hecht (Chief Legal Officer) sold 16,667 shares at about $7.45 ($124K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,243,174 shares. | SEC filing Filed Feb 2, 2026 |
| Jan 8, 2026 | Planned (10b5-1) | Kevin McCulloch (President / COO) sold 15,000 shares at $8.00 ($120K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,685,426 shares. | SEC filing Filed Jan 9, 2026 |
| Jan 5, 2026 | Planned (10b5-1) | John Patrick Shannon Jr (CEO and Director) sold 24,907 shares at about $7.08 ($176K), marked as a 10b5-1 plan trade. Holdings down 1% to 2,705,346 shares. | SEC filing Filed Jan 6, 2026 |
| Jan 2, 2026 | Planned (10b5-1) | Beth Hecht (Chief Legal Officer) sold 16,667 shares at about $7.43 ($124K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,308,103 shares. | SEC filing Filed Jan 5, 2026 |
| Dec 19, 2025 | Sale | John Johnson (Director) sold 135,400 shares at about $7.22 ($978K). Holdings down 16% to 698,083 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 19, 2025 |
| Dec 12, 2025 | Planned (10b5-1) | Barbara-Jean Anne Bormann-Kennedy (Director) sold 15,000 shares at about $7.09 ($106K), marked as a 10b5-1 plan trade. Holdings down 10% to 142,500 shares. | SEC filing Filed Dec 15, 2025 |
| Dec 1, 2025 | Planned (10b5-1) | Beth Hecht (Chief Legal Officer) sold 16,667 shares at about $7.01 ($117K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,320,176 shares. | SEC filing Filed Dec 2, 2025 |
| Nov 13, 2025 | Planned (10b5-1) | John Patrick Shannon Jr (CEO and Director) sold 23,242 shares at about $7.46 ($173K), marked as a 10b5-1 plan trade. Holdings down 1% to 2,643,153 shares. | SEC filing Filed Nov 17, 2025 |
| Nov 11, 2025 | Planned (10b5-1) | Beth Hecht (Chief Legal Officer) sold 16,667 shares at about $7.40 ($123K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,336,843 shares. | SEC filing Filed Nov 13, 2025 |
19 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 2, 2026, 8:05 AM ET 8-K | Executive or director change (Item 5.02) Reg FD disclosure (Item 7.01) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow XERS in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.